secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001999371-25-021194
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix announces TNX-4800 Phase 1 data, plans 2026 FDA meeting for Phase 2/3 Lyme disease prevention
--------------------------------------------------------------------------------

- Phase 1 study of TNX-4800 in 44 subjects showed mean half-life of 62-69 days; detectable up to 12 months.
- Company will meet with FDA in 2026 to explore Phase 2/3 development options including a controlled human infection model (CHIM).
- Expects GMP investigational product available for clinical testing in early 2027.
- TNX-4800 targets OspA of Borrelia burgdorferi; designed as annual seasonal prophylaxis for Lyme disease.
- Anti-drug antibodies in <10% of subjects with no impact on PK; most adverse events mild or moderate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125021194/0001999371-25-021194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125021194/tonix-8k_122925.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-021194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer